Aclaris Therapeutics, Inc.
NASDAQ:ACRS
2.92 (USD) • At close December 26, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Aclaris Therapeutics, Inc. |
Symbool | ACRS |
Munteenheid | USD |
Prijs | 2.915 |
Beurswaarde | 208,221,074 |
Dividendpercentage | 0% |
52-weken bereik | 0.856 - 5.17 |
Industrie | Diagnostics & Research |
Sector | Healthcare |
CEO | Dr. Douglas J. Manion Frcp(C), M.D. |
Website | https://www.aclaristx.com |
An error occurred while fetching data.
Over Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)